Identification of molecular targets for lung adenocarcinoma treatment through proteome analysis of phospholyrated kinases
Project/Area Number |
20390363
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Thoracic surgery
|
Research Institution | Tohoku University |
Principal Investigator |
SAKURADA Akira Tohoku University, 病院, 助教 (60360872)
|
Co-Investigator(Kenkyū-buntansha) |
ENDO Chiaki 東北大学, 病院, 講師 (80333813)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2010: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2009: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2008: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
|
Keywords | 肺癌 / EGFR遺伝子 / キナーゼ / プロテオーム / リン酸化 / GRLF1 |
Research Abstract |
Phospholyration of protein is important in signal transduction. We screened phospholyrated proteins in lung adenocarcinoma cell by using mass spectrometry to identify molecular targets for lung cancer treatment. Some proteins, including GFRF1/p190 A RhoGAP, were strongly controlled by EGFR protein. Functional analysis revealed that GFRF1/p190 A RhoGAP protein controls lung cancer cell proliferation through regulating MEK/ERK pathway. This protein could be a candidate of molecular treatment of lung adenocarcinoma.
|
Report
(4 results)
Research Products
(28 results)
-
[Journal Article] Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.2011
Author(s)
Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maitre A, Gandara D, Johnson DH, Rigas JR, Seymour L, Shepherd FA.
-
Journal Title
J Thorac Oncol
Volume: 6
Pages: 139-147
Related Report
Peer Reviewed
-
-
-
-
-
-
-
[Journal Article] Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.2009
Author(s)
Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N, Boerner S, Sakurada A, Ludkovski O, Ma C, Squire J, Liu G, Shepherd FA, Tsao MS, Leighl NB
-
Journal Title
J Clin Oncol 27
Pages: 6229-6236
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
[Journal Article] Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 212008
Author(s)
Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS
-
Journal Title
J Clin Oncol 26
Pages: 4268-4275
Related Report
Peer Reviewed
-
[Journal Article] Phase II study of erlotinib in recurrent or metastatic endometrial cancer : NCIC IND-1482008
Author(s)
Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A
-
Journal Title
J Clin Oncol 26
Pages: 4319-4325
Related Report
Peer Reviewed
-
-
[Journal Article] siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma2008
Author(s)
Yamanaka S, Gu Z, Sato M, Fujisaki R, Inomata K, Sakurada A, Inoue A, Nukiwa, T, Kondo T, Horii A
-
Journal Title
Pathobiologyl 75
Pages: 2-8
Related Report
Peer Reviewed
-
-
-
-
-
-
-